Here's why the Imugene (ASX:IMU) share price is rising 9% today

The Imugene Limited (ASX: IMU) share price is rising today after announcing the successful outcome from the Cohort Review Committee (CRC) regarding its PD1-Vaxx immunotherapy.

| More on:
Female scientist in lab examines coronavirus vaccine

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Imugene Limited (ASX: IMU) share price is on the rise today. This comes after the company received a successful outcome from the Cohort Review Committee (CRC) regarding its PD1-Vaxx immunotherapy.

PD1-Vaxx is a B-cell immunotherapy designed to treat tumours by producing polyclonal antibodies that block PD-1 signalling, causing an anti-cancer effect.

During mid-afternoon trade, the Imugene shares are up 9.5% to 12 cents.

First checkpoint passed

The Imugene share price is rising deeper into positive territory following the release.

According to Imugene, the CRC cleared the pathway for phase I clinical trials to be proceed with a higher dose of PD1-Vaxx.

Following patient data review, CRC unanimously decided that the immunotherapy candidate is safe with no dose-limiting toxicities or adverse reactions.

CRC advised that Imugene can now administer a stronger 50 micrograms 'mid-dose' level to patients in the first-stage clinical trial.

Originally, the company provided a dose of just 10 micrograms of PD1-Vaxx to participants as monotherapy during the initial study.

Imugene noted that clinicians from Australia and the United States will also look into the underlying benefits of PD1-Vaxx. This includes understanding if patients who are treated with the PD1-Vaxx as a monotherapy will prolong survival, delay tumour progression, or reduce tumour discomfort in patients with lung cancer.

Words from management

Imugene Managing Director and CEO, Ms. Leslie Chong, hailed the positive results, saying:

We are pleased with the results that we have seen so far with no observed toxicity. Everyone supporting the study who are involved in developing this important new cancer therapy are very encouraged by the progress to date. We look forward to continuing this study and reporting to the market of its progress.

About the Imugene share price

The Imugene share price has performed relatively well over the past 12 months, up over 228%.

Its shares reached a 52-week low of 1.6 cents before surging high in late 2020, recording an all-time high of 14 cents.

Based on the current share price, the company's market capitalisation now presides at $545 million.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A man in his 30s holds his laptop and operates it with his other hand as he has a look of pleasant surprise on his face as though he is learning something new or finding hidden value in something on the screen.
Broker Notes

How this undervalued ASX All Ords share could rocket 80% in a year

A leading fund manager expects a big turnaround for this beaten-down ASX All Ords stock.

Read more »

Man looking happy and excited as he looks at his mobile phone.
Share Gainers

Why Champion Iron, Clarity Pharmaceuticals, St Barbara, and Woodside shares are charging higher today

These shares are having a good session today. But why are investors buying them?

Read more »

Frustrated stock trader screaming while looking at mobile phone, symbolising a falling share price.
Share Fallers

Why ALS, Black Cat, Boss Energy, and Soul Patts shares are falling today

These shares are falling on Thursday. Let's find out why.

Read more »

A car dealer stands amid a selection of cars parked in a showroom.
Broker Notes

Up 77% in a year, guess how much more upside Macquarie tips for Eagers Automotive shares

Macquarie released its latest analysis on Eagers Automotive fast rising shares this morning.

Read more »

Boy looks quizzical standing in front of a graph.
Share Market News

Big ASX 200 news! Stock market whipsaws as Trump's tariffs struck down

Markets initially surged on news that Trump's tariffs are out.

Read more »

Frustrated and shocked business woman reading bad news online from phone.
Broker Notes

Guess which ASX 200 share Goldman Sachs just downgraded

The broker is calling time on this stock's rally.

Read more »

Contented looking man leans back in his chair at his desk and smiles.
Share Market News

5 things to watch on the ASX 200 on Thursday

Here's what to expect on the local market today.

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Broker Notes

These ASX 200 shares can rise 20% to 50%

Let's see which shares are being tipped to rocket from current levels.

Read more »